These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Shapiro MD; Fazio S Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970 [TBL] [Abstract][Full Text] [Related]
3. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple. Vincent J Clin Pharmacol Ther; 2018 Aug; 104(2):220-224. PubMed ID: 30117592 [TBL] [Abstract][Full Text] [Related]
4. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. Filippatos TD; Liontos A; Christopoulou EC; Elisaf MS Curr Vasc Pharmacol; 2019; 17(4):332-340. PubMed ID: 29424317 [TBL] [Abstract][Full Text] [Related]
5. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Kim K; Ginsberg HN; Choi SH Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170 [TBL] [Abstract][Full Text] [Related]
6. Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications. Ridker PM Circulation; 2018 Apr; 137(17):1763-1766. PubMed ID: 29273581 [No Abstract] [Full Text] [Related]
7. Lipid pharmacotherapy for treatment of atherosclerosis. Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590 [TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
10. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia. Wiggins BS J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550 [TBL] [Abstract][Full Text] [Related]
11. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Tuñón J; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Hoefer IE; Ketelhuth DFJ; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Bäck M Cardiovasc Res; 2019 Jan; 115(1):10-19. PubMed ID: 30534957 [TBL] [Abstract][Full Text] [Related]
12. Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits? Vani A; Underberg JA Clin Pharmacol Ther; 2018 Aug; 104(2):290-296. PubMed ID: 29882959 [TBL] [Abstract][Full Text] [Related]
14. A new dawn for managing dyslipidemias: The era of rna-based therapies. Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975 [TBL] [Abstract][Full Text] [Related]
15. Clinical controversies in lipid management. Tziomalos K Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164 [TBL] [Abstract][Full Text] [Related]
16. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668 [TBL] [Abstract][Full Text] [Related]